BP
REGN icon

BNP Paribas’s Regeneron Pharmaceuticals REGN Stock Holding History

BNP Paribas’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$726K Sell
940
-60
-6% -$45.9K 0.02% 193
2025
Q4 		$772K Buy
1,000
+134
+15% +$91K 0.02% 193
2025
Q3 		$487K Buy
866
+221
+34% +$125K 0.01% 195
2025
Q2 		$339K Sell
645
-1,093
-63% -$610K 0.01% 215
2025
Q1 		$1.1M Buy
1,738
+60
+4% +$41.3K 0.05% 160
2024
Q4 		$1.2M Sell
1,678
-55
-3% -$46.2K 0.01% 156
2024
Q3 		$1.82M Buy
1,733
+243
+16% +$270K 0.08% 110
2024
Q2 		$1.57M Sell
1,490
-296
-17% -$287K 0.08% 109
2024
Q1 		$1.72M Buy
+1,786
New +$1.7M 0.08% 111

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BNP Paribas's REGN Position: Q1 2026 in Review

BNP Paribas reduced its Regeneron Pharmaceuticals (REGN) stake by 6% in Q1 2026, selling an estimated $45.9K and leaving 940 shares worth $726K. The position accounts for 0.02% of the portfolio, ranked #193.

BNP Paribas first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.82M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • BNP Paribas held 940 shares of Regeneron Pharmaceuticals worth $726K as of Q1 2026.
  • BNP Paribas sold 60 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $45.9K.
  • Regeneron Pharmaceuticals made up 0.02% of BNP Paribas's portfolio in Q1 2026, its #193 holding.
  • BNP Paribas first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • BNP Paribas's Regeneron Pharmaceuticals position peaked at $1.82M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on BNP Paribas's 13F filing for Q1 2026, filed 12 May 2026.